Report Overview

Indian Alport Syndrome Treatment market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Alport Syndrome is the hereditary genetic disorder characterized by glomerulonephritis, abnormal vision, and acute hearing loss and end-stage renal disease. Alport Syndrome is also called the hereditary nephritis. Alport syndrome is the rare disease usually affecting the male population. Patients commonly needs renal replacement therapy , renal transplantation in pediatric patients is a successful procedure, with 1- and 5-year patient survival rates of 98%, the range takes into account of the differences between living and deceased donors. . Recurrent gross hematuria usually occurs in 40%60% cases during infancy and early childhood. Proteinuria develops later. Bilateral sensorineural hearing loss is the second most commonly occurring in 55% in males and 45% in females in India.



Market Drivers

The growing prevalence of the genetic disorder is expected to be the major factor driving the growth of the Alport syndrome treatment market over the forecast period. Increasing high blood pressure problems are secondary factors expected to boost the demand for alport syndrome treatment drugs. Increasing the diagnosis rate due to screening programs, favorable medicare policies, increasing healthcare expenditures are another reason for the growth of the alport syndrome treatment market. Increasing research and development for the treatment of rare diseases is expected to boost the growth of alport syndrome treatment market. The side effect associated with some alport syndrome treatment medication and less awareness regarding diseases among the general population are some of the factors expected to restrain the growth of the alport syndrome treatment market.